(S)-1,2-diaminopropane | 15967-72-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-1,2-diaminopropane
• 英文别名: (S)-propane-1,2-diamine；(2S)-propane-1,2-diamine
• CAS: 15967-72-3
• 化学式: C₃H₁₀N₂
• mdl: MFCD00067104
• 分子量: 74.1258
• InChiKey: AOHJOMMDDJHIJH-VKHMYHEASA-N

物化性质

• 沸点：
  117.3±8.0 °C(Predicted)
• 密度：
  0.863±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-1,2-diaminopropane 生成 (S)-(+)-1,2-丙二胺-N,N,N',N'-四乙酸
  参考文献：
  名称：

  The Preparation of 1,2-Propylenediaminetetraacetic Acid and its Resolution through the Cobalt(III) Complex

  摘要：

  DOI：

  10.1021/ja01521a010
• 作为产物：
  描述：

  L-氨基丙醇 在 palladium on activated charcoal 叠氮磷酸二苯酯 、 氢气 作用下， 生成 (S)-1,2-diaminopropane
  参考文献：
  名称：

  Prevention and treatment of cardiac conditions

  摘要：

  本发明提供了一种治疗与铁和钙过载相关症状的方法，包括给予有效量的地拉唑喜或公式（IA）、（IB）或（IC）的非地拉唑喜化合物或其药用可接受的盐、互变异构体或立体异构体。

  公开号：

  US20080275036A1

文献信息

• Methods of preparing manganese complexes of nitrogen-containing
  申请人：Monsanto Company

  公开号：US05610293A1

  公开（公告）日：1997-03-11

  The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

  本发明涉及超氧化物歧化酶（SOD）的低分子量模拟物，其化学式如下：##STR1## 其中R、R'、R₁、R'₁、R₂、R'₂、R₃、R'₃、R₄、R'₄、R₅、R'₅、R₆、R'₆、R₇、R'₇、R₈、R'₈、R₉和R'₉以及X、Y、Z和n的定义如本文所述，可用作治疗炎症性疾病状态和紊乱、缺血/再灌注损伤、中风、动脉粥样硬化、高血压和所有其他由氧化剂引起的组织损伤或损伤的条件。
• Manganese complexes of nitrogen-containing macrocyclic ligands effective
  申请人：G. D. Searle & Co.

  公开号：US05874421A1

  公开（公告）日：1999-02-23

  The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

  本发明涉及超氧化物歧化酶（SOD）的低分子量模拟物，其化学式为：##STR1## 其中R、R'、R₁、R'₁、R₂、R'₂、R₃、R'₃、R₄、R'₄、R₅、R'₅、R₆、R'₆、R₇、R'₇、R₈、R'₈、R₉和R'₉以及X、Y、Z和n的定义如本文所述，可用作治疗炎症性疾病状态和紊乱、缺血/再灌注损伤、中风、动脉粥样硬化、高血压和所有其他由氧化剂引起的组织损伤或损伤的条件的治疗剂。
• MST1 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Augeri David John

  公开号：US20120225857A1

  公开（公告）日：2012-09-06

  Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.

  揭示了用于抑制哺乳动物Ste20样激酶1（MST1）的化合物，以及包含它们的组合物和在治疗、管理或预防炎症性或自身免疫疾病或紊乱中使用它们的方法。
• Process for preparing enantiomerically pure
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05463049A1

  公开（公告）日：1995-10-31

  Process for preparing enantiomerically pure imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thiones of formula ##STR1## starting from 2,6-dihalo-3-nitrobenzyl derivatives (II) and suitably N-protected 1,2-diaminopropanes (III) ##STR2## Novel enantiomerically pure intermediates of formula (III) and (IV) prepared in the course of the present process.

  制备具有公式##STR1##的立体纯的咪唑[4,5,1-jk][1,4]苯并二氮杂卓-2(1H)-硫酮的方法，从2,6-二卤代-3-硝基苄基衍生物(II)和适当的N-保护的1,2-二氨基丙烷(III)##STR2##开始。本过程中制备的新颖立体纯中间体为公式(III)和(IV)。
• TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20180155365A1

  公开（公告）日：2018-06-07

  The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I). and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R 1 , R 2 , R 3 and R 7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

  本发明涉及式(I)的四环杂环化合物及其药学上可接受的盐或前药，其中A、X、R1、R2、R3和R7如本文所定义。本发明还涉及包含至少一种四环杂环化合物的组合物，以及使用四环杂环化合物治疗或预防主体中的HIV感染的方法。